产品
编 号：F031243
分子式：C24H25FN6O
分子量：432.49
分子式：C24H25FN6O
分子量：432.49
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
100mg
832
In-stock
200mg
1504
In-stock
500mg
2664
In-stock
结构图
CAS No: 108612-45-9
产品详情
生物活性：
Mizolastine is an orally active, high affinity and specific peripheral histamine H1 receptor antagonist (second generation antihistamine). Mizolastine effectively inhibits mRNA expression of VEGF165, VEGF120, TNF-α and KC. Mizolastine can be used in studies of allergic rhinitis and chronic idiopathic urticarial.
体内研究：
Mizolastine (0.3 mg/kg; p.o.; single daily for 7 days) inhibits production of 5-LOX AA (arachidonic acid) metabolite leukotriene B4 (LTB4), and suppresses expression of 5-LOX, cytosolic PLA2 (cPLA2), 5-LOX-activating protein, and LTB4 receptor mRNA in the AA-induced inflammation model.Animal Model:Male Sprague-Dawley rats (specific-pathogen-free; 234-254 g; 7 to 8-week-old; rat paw edema model).
Dosage:0.3 mg/kg
Administration:Oral gavage; single daily for 7 days.
Result:Significantly reduced paw edema by 21% at 1 h, and by 14?18% between 2 and 4 h.Inhibited inflammatory cell infiltration and significantly reduced levels of LTB4.Suppressed expression of 5?LOX, cPLA2, FLAP and LTB4r mRNA.
体外研究：
Mizolastine (1-10000 nM; 0.5-6 h) shows inhibitory effects on VEGF, KC and TNF-α release in mast cells.Mizolastine (0.1 μM; 4 h) significantly reduces VEGF165, VEGF120, TNF-α and KC mRNA expression in mast cells.
Mizolastine is an orally active, high affinity and specific peripheral histamine H1 receptor antagonist (second generation antihistamine). Mizolastine effectively inhibits mRNA expression of VEGF165, VEGF120, TNF-α and KC. Mizolastine can be used in studies of allergic rhinitis and chronic idiopathic urticarial.
体内研究：
Mizolastine (0.3 mg/kg; p.o.; single daily for 7 days) inhibits production of 5-LOX AA (arachidonic acid) metabolite leukotriene B4 (LTB4), and suppresses expression of 5-LOX, cytosolic PLA2 (cPLA2), 5-LOX-activating protein, and LTB4 receptor mRNA in the AA-induced inflammation model.Animal Model:Male Sprague-Dawley rats (specific-pathogen-free; 234-254 g; 7 to 8-week-old; rat paw edema model).
Dosage:0.3 mg/kg
Administration:Oral gavage; single daily for 7 days.
Result:Significantly reduced paw edema by 21% at 1 h, and by 14?18% between 2 and 4 h.Inhibited inflammatory cell infiltration and significantly reduced levels of LTB4.Suppressed expression of 5?LOX, cPLA2, FLAP and LTB4r mRNA.
体外研究：
Mizolastine (1-10000 nM; 0.5-6 h) shows inhibitory effects on VEGF, KC and TNF-α release in mast cells.Mizolastine (0.1 μM; 4 h) significantly reduces VEGF165, VEGF120, TNF-α and KC mRNA expression in mast cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备